These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 19467723)

  • 1. Regulatory aspects of biosimilars in Europe.
    Zuñiga L; Calvo B
    Trends Biotechnol; 2009 Jul; 27(7):385-7. PubMed ID: 19467723
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The problematic of original and generic drugs and biosimilars--switching of drugs today and tomorrow with the main targeting on biotechnologies-associated risks].
    Svoboda T
    Klin Onkol; 2010; 23(6):416-20. PubMed ID: 21351418
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Basic facts about biosimilars.
    Nowicki M
    Kidney Blood Press Res; 2007; 30(5):267-72. PubMed ID: 17622764
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Addressing the health technology assessment of biosimilar pharmaceuticals.
    Stewart A; Aubrey P; Belsey J
    Curr Med Res Opin; 2010 Sep; 26(9):2119-26. PubMed ID: 20649394
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Challenges in the anticipation of biosimilars: how must a P&T committee gear up?
    Tadlock C
    Manag Care Interface; 2007 Apr; 20(4):12, 14. PubMed ID: 17536251
    [No Abstract]   [Full Text] [Related]  

  • 6. Biosimilar drugs : concerns and opportunities.
    Genazzani AA; Biggio G; Caputi AP; Del Tacca M; Drago F; Fantozzi R; Canonico PL
    BioDrugs; 2007; 21(6):351-6. PubMed ID: 18020619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. European regulatory guidelines for biosimilars.
    Wiecek A; Mikhail A
    Nephrol Dial Transplant; 2006 Oct; 21 Suppl 5():v17-20. PubMed ID: 16959790
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biosimilars and innovation: an analysis of the possibility of increased competition in biopharmaceuticals.
    Blackstone EA; Fuhr JP
    Future Med Chem; 2010 Nov; 2(11):1641-9. PubMed ID: 21428836
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biosimilars: a regulatory perspective from America.
    Kay J
    Arthritis Res Ther; 2011 May; 13(3):112. PubMed ID: 21586106
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessing the bioequivalence of biosimilars The Retacrit case.
    Schellekens H
    Drug Discov Today; 2009 May; 14(9-10):495-9. PubMed ID: 19429509
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biosimilars: it's not as simple as cost alone.
    Roger SD; Goldsmith D
    J Clin Pharm Ther; 2008 Oct; 33(5):459-64. PubMed ID: 18834359
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biosimilars--science, status, and strategic perspective.
    Kresse GB
    Eur J Pharm Biopharm; 2009 Aug; 72(3):479-86. PubMed ID: 19286455
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Follow-on protein products: scientific issues, developments and challenges.
    Rathore AS
    Trends Biotechnol; 2009 Dec; 27(12):698-705. PubMed ID: 19846228
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Challenges in the implementation of trastuzumab biosimilars: an expert panel's recommendations.
    Pivot X; Aulagner G; Blay JY; Fumoleau P; Kaliski A; Sarkozy F; Limat S
    Anticancer Drugs; 2015 Nov; 26(10):1009-16. PubMed ID: 26352219
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Follow-on biologics: challenges of the "next generation".
    Schellekens H
    Nephrol Dial Transplant; 2005 May; 20 Suppl 4():iv31-36. PubMed ID: 15827057
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How similar do 'biosimilars' need to be?
    Schellekens H
    Nat Biotechnol; 2004 Nov; 22(11):1357-9. PubMed ID: 15529154
    [No Abstract]   [Full Text] [Related]  

  • 17. Biosimilars: how similar or dissimilar are they?
    Roger SD
    Nephrology (Carlton); 2006 Aug; 11(4):341-6. PubMed ID: 16889575
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biosimilars: opportunity or cause for concern?
    Roger SD; Mikhail A
    J Pharm Pharm Sci; 2007; 10(3):405-10. PubMed ID: 17727803
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New preparations comprising recombinant human growth hormone: deliberations on the issue of biosimilars.
    Ranke MB
    Horm Res; 2008; 69(1):22-8. PubMed ID: 18057913
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The advent of biosimilars: new rules to guarantee patient safety].
    Gesualdo L; Abbracchio MP; Dammacco F; Goffredo F; Zanella A; Ronco C
    G Ital Nefrol; 2009; 26(2):161-70. PubMed ID: 19382072
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.